loading
Biodexa Pharmaceuticals Plc Adr stock is traded at $6.70, with a volume of 112.22K. It is down -14.65% in the last 24 hours and down -22.98% over the past month. Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
See More
Previous Close:
$7.85
Open:
$7.65
24h Volume:
112.22K
Relative Volume:
0.46
Market Cap:
$39.65M
Revenue:
$644.60K
Net Income/Loss:
$-9.87M
P/E Ratio:
-0.008
EPS:
-837.9618
Net Cash Flow:
$-9.02M
1W Performance:
-23.86%
1M Performance:
-22.98%
6M Performance:
-84.79%
1Y Performance:
-95.95%
1-Day Range:
Value
$5.852
$7.70
1-Week Range:
Value
$5.852
$9.00
52-Week Range:
Value
$5.852
$169.72

Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Company Profile

Name
Name
Biodexa Pharmaceuticals Plc Adr
Name
Phone
-
Name
Address
-
Name
Employee
13
Name
Twitter
Name
Next Earnings Date
2024-06-13
Name
Latest SEC Filings
Name
BDRX's Discussions on Twitter

Compare BDRX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
BDRX
Biodexa Pharmaceuticals Plc Adr
6.70 39.65M 644.60K -9.87M -9.02M -837.96
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
462.13 117.32B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
558.87 58.89B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
401.80 51.14B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
673.80 41.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
299.01 32.59B 3.81B -644.79M -669.77M -6.24

Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-08-24 Initiated Ladenburg Thalmann Buy

Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Latest News

pulisher
Jul 31, 2025

Biodexa completes ADR ratio change to 1:100,000 ordinary shares By Investing.com - Investing.com South Africa

Jul 31, 2025
pulisher
Jul 31, 2025

Biodexa Pharmaceuticals Implements ADR Ratio Change - TipRanks

Jul 31, 2025
pulisher
Jul 31, 2025

ADR Ratio Change Effective | BDRX Stock News - GuruFocus

Jul 31, 2025
pulisher
Jul 31, 2025

ADR Ratio Change Effective - GlobeNewswire

Jul 31, 2025
pulisher
Jul 31, 2025

Biodexa Implements Major ADR Restructuring: 10,000 to 100,000 Shares Per ADR Change Now Active - Stock Titan

Jul 31, 2025
pulisher
Jul 28, 2025

Biodexa advances FAP treatment with phase 3 trial initiation By Investing.com - Investing.com South Africa

Jul 28, 2025
pulisher
Jul 28, 2025

Breakthrough FAP Treatment Enters Phase 3: How Biodexa Could Transform $7B Cancer Prevention Market - Stock Titan

Jul 28, 2025
pulisher
Jul 16, 2025

Biodexa Pharmaceuticals Announces ADR Ratio Change Effective July 31, 2025 - The Globe and Mail

Jul 16, 2025
pulisher
Jul 15, 2025

Biodexa Pharmaceuticals Announces Reverse ADR Split to Regain Nasdaq Compliance - AInvest

Jul 15, 2025
pulisher
Jul 15, 2025

Biodexa Pharmaceuticals PLC Announces ADR Ratio Change Effective July 31, 2025 - Nasdaq

Jul 15, 2025
pulisher
Jul 15, 2025

Biodexa Pharmaceuticals to implement 1:10 ADR ratio change - Investing.com

Jul 15, 2025
pulisher
Jul 15, 2025

Biodexa Pharmaceuticals PLC Announces ADR Ratio Change from 1:10 to 1:100,000. - AInvest

Jul 15, 2025
pulisher
Jul 15, 2025

MFS Extends Deadline for Liquidity Event for MFS Investment Grade Municipal Trust - AInvest

Jul 15, 2025
pulisher
Jul 15, 2025

ADR Ratio Change - GlobeNewswire

Jul 15, 2025
pulisher
Jul 15, 2025

Biodexa Plans Major ADR Restructuring: 1:10 Reverse Split to Meet Nasdaq Requirements - Stock Titan

Jul 15, 2025
pulisher
Jul 14, 2025

Biodexa files European clinical trial application for FAP treatment By Investing.com - Investing.com India

Jul 14, 2025
pulisher
Jul 14, 2025

Biodexa files European clinical trial application for FAP treatment - Investing.com

Jul 14, 2025
pulisher
Jul 14, 2025

Biodexa's $20M-Backed Phase 3 Trial for Rare Cancer Prevention Drug Expands to Europe - Stock Titan

Jul 14, 2025
pulisher
Jul 14, 2025

SMX (Security Matters) Plc (SMX) Stock: Navigating Drops and Gains - investchronicle.com

Jul 14, 2025
pulisher
Jul 14, 2025

Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) - GlobeNewswire

Jul 14, 2025
pulisher
Jul 09, 2025

Company’s Banking Stock: Dissecting a 60.04% Quarterly Revenue Decline Amid Growth - investchronicle.com

Jul 09, 2025
pulisher
Jun 27, 2025

Biodexa Pharmaceuticals Secures 100% Shareholder Approval for Key Corporate Decisions at AGM - Stock Titan

Jun 27, 2025
pulisher
Jun 25, 2025

Biodexa Announces Activation of First Clinical Study Site - GlobeNewswire

Jun 25, 2025
pulisher
Jun 23, 2025

Biodexa Unveils Phase 3 FAP Trial "Serenta": New Hope for Rare Disease Patients - Stock Titan

Jun 23, 2025
pulisher
Jun 18, 2025

Biodexa enrolls first patient in type 1 diabetes drug trial - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Breakthrough Oral Diabetes Drug Enters Phase 2 Trial, Could Replace Daily Insulin Injections for Millions - Stock Titan

Jun 18, 2025
pulisher
Jun 13, 2025

Biodexa Pharmaceuticals changes share nominal value By Investing.com - Investing.com South Africa

Jun 13, 2025
pulisher
Jun 13, 2025

Biodexa Pharmaceuticals changes share nominal value - Investing.com

Jun 13, 2025
pulisher
Jun 11, 2025

Biodexa shareholders approve all resolutions at general meeting By Investing.com - Investing.com India

Jun 11, 2025
pulisher
Jun 11, 2025

Biodexa shareholders approve all resolutions at general meeting - Investing.com

Jun 11, 2025
pulisher
Jun 04, 2025

Phase 2 Trial Begins: Biodexa's Breakthrough Type 1 Diabetes Drug Shows Promise in Human Cells - Stock Titan

Jun 04, 2025
pulisher
May 22, 2025

Biodexa secures additional $3M for cancer drug trial By Investing.com - Investing.com India

May 22, 2025
pulisher
May 22, 2025

BDRXBiodexa Pharmaceuticals plc Latest Stock News & Market Updates - Stock Titan

May 22, 2025
pulisher
May 22, 2025

Biodexa secures additional $3M for cancer drug trial - Investing.com

May 22, 2025
pulisher
May 20, 2025

Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Could Find a Support Soon, Here - sharewise

May 20, 2025
pulisher
May 20, 2025

Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Nasdaq

May 20, 2025
pulisher
May 15, 2025

Biodexa Pharmaceuticals adjusts warrant exercise price - Investing.com

May 15, 2025
pulisher
May 15, 2025

Biodexa Pharmaceuticals adjusts warrant exercise price By Investing.com - Investing.com India

May 15, 2025
pulisher
May 12, 2025

Biodexa gains orphan drug status in EU for colon disease treatment - Investing.com

May 12, 2025
pulisher
May 12, 2025

Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP - GlobeNewswire

May 12, 2025
pulisher
May 02, 2025

Biodexa Special Resolution Falls 4% Short: Chairman Promises New Fundraising Proposals - Stock Titan

May 02, 2025
pulisher
Apr 24, 2025

What Makes Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) a New Buy Stock - MSN

Apr 24, 2025
pulisher
Apr 17, 2025

Biodexa Shareholders to Vote on Strategic Share Subdivision Plan: Key Meeting Details Revealed - Stock Titan

Apr 17, 2025
pulisher
Apr 11, 2025

Preliminary Results for the Year Ended 31 December 2024 - GlobeNewswire

Apr 11, 2025
pulisher
Mar 19, 2025

Biodexa Pharmaceuticals advances FAP treatment trial By Investing.com - Investing.com South Africa

Mar 19, 2025
pulisher
Mar 19, 2025

Biodexa Pharmaceuticals advances FAP treatment trial - Investing.com India

Mar 19, 2025
pulisher
Mar 19, 2025

With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter - BioSpace

Mar 19, 2025
pulisher
Mar 10, 2025

Biodexa gets FDA nod for Phase 3 eRapa study in FAP - Investing.com India

Mar 10, 2025
pulisher
Mar 10, 2025

FDA Clears Biodexa's Phase 3 Protocol for Rare Disease Drug eRapa - Stock Titan

Mar 10, 2025
pulisher
Mar 07, 2025

Why Plus Therapeutics, Inc. (PSTV) Soared on Thursday - Yahoo Finance

Mar 07, 2025
pulisher
Mar 06, 2025

Biodexa selects Precision as CRO for eRapa Phase 3 study in Europe - Investing.com

Mar 06, 2025

Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$75.59
price up icon 0.93%
$37.11
price up icon 0.84%
$108.69
price up icon 1.31%
$27.07
price up icon 2.65%
$107.34
price down icon 0.15%
biotechnology ONC
$299.01
price down icon 0.70%
Cap:     |  Volume (24h):